OS - OneStream, Inc. Class A Common Stock

Price: -- -- | CONSENSUS: Hold DETAILS | PRICE TARGET: $24.00 DETAILS

Stock News

Advanced Polymer Coatings (APC) Collaborates with Albert Invent to Scale the Future of Modern R&D Infrastructure for Coatings

AVON, Ohio & OAKLAND, Calif.--(BUSINESS WIRE)--Advanced Polymer Coatings (APC), a global leader in polymer coatings, is making major strides in product development with chemistry AI company Albert Invent to advance and scale its modern R&D infrastructure.Through this partnership, APC is implementing Albert's AI-native operating system (OS) for chemistry and materials science to centralize experimental data, capture institutional knowledge, and enable more efficient collaboration across resea.

Jun 23, 2026 05:00 AM • businesswire.com

Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL

Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited

Jun 14, 2026 12:00 AM • gurufocus.com

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

[url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously

Jun 13, 2026 09:00 AM • gurufocus.com

$New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myel$

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myel

New TALVEYÂ (talquetamab-tgvs) plus DARZALEX FASPROÂ (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combi

Jun 13, 2026 03:00 AM • gurufocus.com

Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progr

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (MonjuviÂ/Min

Jun 13, 2026 02:00 AM • gurufocus.com

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit

[url="]BeOne Medicines Ltd.[/url] (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 datas

Jun 11, 2026 04:00 AM • gurufocus.com

WilliamsMarston's AIT Consulting Services Wins OneStream AI Excellence Award

BOSTON--(BUSINESS WIRE)--WilliamsMarston, a national leader in complex accounting, tax, technology, transaction, and valuation advisory services, is proud to recognize AIT Consulting Services (“AIT”) for receiving the 2026 AI Excellence Award from OneStream, which honors partners delivering measurable business impact through AI-powered finance solutions. AIT, a WilliamsMarston company and a Diamond OneStream implementation partner, was recognized for its role in helping MB2 Dental—a fast-growin.

Jun 10, 2026 05:02 AM • businesswire.com

Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has approved the Biologics License Appl

Jun 08, 2026 05:00 PM • gurufocus.com

Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6

Further positive results from the Phase III SERENA-6 trial showed AstraZeneca's camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor â palbociclib

Jun 02, 2026 05:00 AM • gurufocus.com

IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late

IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Li

Jun 01, 2026 08:00 AM • gurufocus.com

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMON

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced positive overall survival (OS) results from the Phase III HARMONi-6 trial, conducted in China and spons

May 31, 2026 06:00 AM • gurufocus.com

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

[url="]Pfizer Inc. [/url](NYSE: PFE) today announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 B

May 31, 2026 05:00 AM • gurufocus.com

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with ea

May 31, 2026 05:00 AM • gurufocus.com

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

[url="]Pfizer Inc. [/url](NYSE: PFE) today announced detailed results from the pivotal Phase 3 TALAPRO-3 study of TALZENNAÂ (talazoparib), an oral poly ADP-ri

May 30, 2026 05:00 AM • gurufocus.com

Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patie

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (MonjuviÂ/Min

May 30, 2026 05:00 AM • gurufocus.com

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

RYBREVANTÂ (amivantamab-vmjw) plus LAZCLUZEÂ (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR

May 29, 2026 11:00 AM • gurufocus.com

Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the latest results from its missi

May 29, 2026 06:00 AM • gurufocus.com

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

AstraZeneca's IMFINZIÂ (durvalumab) in combination with Bacillus Calmette-GuÃrin (BCG) induction and maintenance therapy has been approved in the US for the

May 28, 2026 06:00 PM • gurufocus.com

OneStream Unveils Forward Finance Blueprint to Help CFOs Lead Enterprise AI and Future-Proof the Business

As CFOs take point on leading enterprise AI strategy, new operating model guides Finance in rebuilding workforce, operations, and decision-making in the age of AI ORLANDO, Fla., May 18, 2026 /PRNewswire/ -- OneStream, the AI operating system for modern Finance that unifies core financial and operational processes, embedding the governance, context, and control required to make AI work for Finance, today announced the release of Forward Finance: The New Operating Model for Intelligent Organizations.

May 18, 2026 05:00 AM • prnewswire.com

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer

AstraZeneca and Daiichi Sankyo's ENHERTUÂ (fam-trastuzumab deruxtecan-nxki) has been approved by the US Food and Drug Administration (FDA) for both the neoadj

May 15, 2026 06:00 PM • gurufocus.com

Price Targets

OS - OneStream, Inc. Class A Common Stock

Stock News

Advanced Polymer Coatings (APC) Collaborates with Albert Invent to Scale the Future of Modern R&D Infrastructure for Coatings

Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myel

Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progr

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit

WilliamsMarston's AIT Consulting Services Wins OneStream AI Excellence Award

Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer

Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6

IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMON

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patie

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

OneStream Unveils Forward Finance Blueprint to Help CFOs Lead Enterprise AI and Future-Proof the Business

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer

Price Targets

OneStream transferred with Neutral rating at Piper Sandler

JPMorgan Downgrades OneStream Inc. (OS) to Underweight

OneStream downgraded to Neutral from Outperform at BNP Paribas

OneStream downgraded to Equal Weight from Overweight at Stephens

OneStream downgraded to Hold from Buy at Loop Capital

OneStream downgraded to Market Perform from Outperform at BMO Capital

OneStream downgraded to Equal Weight from Overweight at Morgan Stanley

OneStream downgraded to Neutral from Outperform at Mizuho

OneStream downgraded to Hold from Buy at Truist

OneStream downgraded to Neutral from Outperform at Baird

OneStream downgraded to Neutral from Outperform at Wedbush

OneStream initiated with a Buy at BTIG

OneStream price target raised to $33 from $30 at Mizuho

OneStream price target lowered to $27 from $35 at Scotiabank

OneStream initiated with an Outperform at BNP Paribas Exane

OneStream price target lowered to $27 from $34 at Morgan Stanley

OneStream Inc. (OS) PT Raised to $37 at Piper Sandler

BMO Capital Starts OneStream Inc. (OS) at Outperform

OneStream price target raised to $34 from $32 at Raymond James

Loop Capital Reiterates Buy Rating on OneStream Inc. (OS)